Logo image of ICPT

INTERCEPT PHARMACEUTICALS IN (ICPT) Stock Fundamental Analysis

NASDAQ:ICPT - Nasdaq - US45845P1084 - Common Stock - Currency: USD

19  +0.04 (+0.21%)

After market: 19 0 (0%)

Fundamental Rating

2

ICPT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. ICPT has a bad profitability rating. Also its financial health evaluation is rather negative. ICPT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ICPT had negative earnings in the past year.
In the past year ICPT has reported a negative cash flow from operations.
ICPT had negative earnings in 4 of the past 5 years.
ICPT had a negative operating cash flow in each of the past 5 years.
ICPT Yearly Net Income VS EBIT VS OCF VS FCFICPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M -400M

1.2 Ratios

The Return On Assets of ICPT (-15.67%) is better than 84.91% of its industry peers.
ICPT has a Return On Equity (-85.76%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROIC N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICPT Yearly ROA, ROE, ROICICPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

1.3 Margins

Looking at the Gross Margin, with a value of 99.80%, ICPT belongs to the top of the industry, outperforming 99.17% of the companies in the same industry.
ICPT's Gross Margin has been stable in the last couple of years.
ICPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
ICPT Yearly Profit, Operating, Gross MarginsICPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

ICPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICPT has been increased compared to 1 year ago.
ICPT has a better debt/assets ratio than last year.
ICPT Yearly Shares OutstandingICPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
ICPT Yearly Total Debt VS Total AssetsICPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

ICPT has an Altman-Z score of -5.03. This is a bad value and indicates that ICPT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.03, ICPT is doing worse than 66.17% of the companies in the same industry.
A Debt/Equity ratio of 3.12 is on the high side and indicates that ICPT has dependencies on debt financing.
With a Debt to Equity ratio value of 3.12, ICPT is not doing good in the industry: 85.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Altman-Z -5.03
ROIC/WACCN/A
WACC10.19%
ICPT Yearly LT Debt VS Equity VS FCFICPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M 600M

2.3 Liquidity

ICPT has a Current Ratio of 4.22. This indicates that ICPT is financially healthy and has no problem in meeting its short term obligations.
ICPT's Current ratio of 4.22 is in line compared to the rest of the industry. ICPT outperforms 42.45% of its industry peers.
ICPT has a Quick Ratio of 4.22. This indicates that ICPT is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.22, ICPT perfoms like the industry average, outperforming 43.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.22
ICPT Yearly Current Assets VS Current LiabilitesICPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ICPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -125.05%.
Looking at the last year, ICPT shows a quite strong growth in Revenue. The Revenue has grown by 14.64% in the last year.
ICPT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.88% yearly.
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%

3.2 Future

The Earnings Per Share is expected to decrease by -22.89% on average over the next years. This is quite bad
Based on estimates for the next years, ICPT will show a small growth in Revenue. The Revenue will grow by 1.71% on average per year.
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICPT Yearly Revenue VS EstimatesICPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ICPT Yearly EPS VS EstimatesICPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10 -15

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ICPT. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 9.11, the valuation of ICPT can be described as reasonable.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ICPT indicates a rather cheap valuation: ICPT is cheaper than 99.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.44, ICPT is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 9.11
ICPT Price Earnings VS Forward Price EarningsICPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICPT Per share dataICPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

ICPT's earnings are expected to decrease with -33.62% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%

More info and screens

0

5. Dividend

5.1 Amount

ICPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTERCEPT PHARMACEUTICALS IN

NASDAQ:ICPT (11/7/2023, 8:02:20 PM)

After market: 19 0 (0%)

19

+0.04 (+0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2023-11-06/amc
Earnings (Next)02-29 2024-02-29/amc
Inst Owners0.17%
Inst Owner Change0%
Ins Owners10.38%
Ins Owner Change0%
Market Cap794.39M
Analysts70
Price Target19.38 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.4%
Min EPS beat(2)73.02%
Max EPS beat(2)117.78%
EPS beat(4)2
Avg EPS beat(4)-7.36%
Min EPS beat(4)-203.66%
Max EPS beat(4)117.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-1.65%
Max Revenue beat(2)3.15%
Revenue beat(4)1
Avg Revenue beat(4)-2.32%
Min Revenue beat(4)-7.75%
Max Revenue beat(4)3.15%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.63%
PT rev (3m)24.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)660.22%
EPS NY rev (1m)0%
EPS NY rev (3m)3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.11
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 11.06
P/tB 11.06
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)2.09
Fwd EY10.98%
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS7.6
BVpS1.72
TBVpS1.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.67%
ROE -85.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.8%
FCFM N/A
ROA(3y)-8.21%
ROA(5y)-26.21%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.45%
GM growth 5Y0.15%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 3.12
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.34%
Cap/Sales 0.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.22
Altman-Z -5.03
F-Score3
WACC10.19%
ROIC/WACCN/A
Cap/Depr(3y)78.24%
Cap/Depr(5y)53.92%
Cap/Sales(3y)0.53%
Cap/Sales(5y)0.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-98.97%
EPS Next Y-122.07%
EPS Next 2Y-41.22%
EPS Next 3Y-33.62%
EPS Next 5Y-22.89%
Revenue 1Y (TTM)14.64%
Revenue growth 3Y4.27%
Revenue growth 5Y16.88%
Sales Q2Q%14.44%
Revenue Next Year3.67%
Revenue Next 2Y6.35%
Revenue Next 3Y4.21%
Revenue Next 5Y1.71%
EBIT growth 1Y30.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.22%
EBIT Next 3Y46.24%
EBIT Next 5YN/A
FCF growth 1Y2.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.28%
OCF growth 3YN/A
OCF growth 5YN/A